Family COMIDA — helping Hispanic families choose healthier foods to prevent and reduce obesity
Official title: Family COMIDA (Consumo de Opciones Más Ideales De Alimentos) (Eating More Ideal Food Options)
Run by Memorial Sloan Kettering Cancer Center · NCT07144800 · Data updated 2026-11-12
This program tests family-centered support (parent counseling, weekly phone coaching, monthly group sessions, and child education) to help Hispanic parents/caregivers and their 8–12-year-old children prevent or reduce obesity.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1319 (estimated) |
| Sponsor | Memorial Sloan Kettering Cancer Center Academic / other |
| Locations | 1 site (New York, New York) |
| Status | Recruiting |
| Started | August 26, 2025 |
| Main results expected | July 31, 2029 |
| Study ends | July 31, 2029 |
| Registry record updated | November 10, 2026 |
| Trial ID | NCT07144800 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Hispanic/Latino adults (≥18) who are parents or primary caregivers of at least one child aged 8–12, who are overweight or have obesity, and who have a cell phone and an internet-connected device for videoconferencing.
✕Probably not a fit
People who are not Hispanic/Latino, who do not care for an eligible 8–12-year-old child, who are normal weight, or who lack phone/internet access are unlikely to be eligible or to benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Family COMIDA compares different family-centered interventions to find which approach best supports weight loss and obesity prevention in Hispanic families. The program delivers parent initial counseling, weekly individual telephone support, monthly parent group support, and education sessions for children. Eligible participants are Hispanic/Latino adults who are parents or primary caregivers of at least one child aged 8–12 and who are overweight or have obesity. All protocol activities are conducted at Memorial Sloan Kettering Cancer Center and sessions may be audio-recorded for program fidelity.
Why it matters
Potential benefit: If successful, families could adopt healthier eating habits that lead to weight loss in parents and lower obesity risk for children.
How similar studies have gone: Previous family-centered and parent-focused interventions have shown meaningful improvements in parent and child weight and health behaviors, so this program builds on existing evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Phase 1 * Age \>= 18 years (per self-report) * Self-identifies as Hispanic/Latino (per self-report) * Seeking, or has used, services at the VDS or MHU (per self-report) * Is the parent or primary caregiver for at least one child aged 8-12 living in their household (per self-report) * Screens as obese (BMI \> 30 kg/m2) or overweight (BMI of 25 - 29.9 kg/m2) (per height and weight measurement in person or per self-report) * Owns a cell phone capable of receiving text messages (per self-report) * Owns an internet connected device (e.g. cell phone, tablet, etc.) capable of conducting videoconference calls (per self-report) * Agrees to be audio-recorded (per self-report) Phase 2 (parent participants) * Age \>= 18 years (per self-report) * Self-identifies as Hispanic/Latino (per self-report) * Seeking, or has used, services at the VDS or MHU (per self-report) * Is the parent or primary caregiver for at least one child aged 8-12 living in their household (per self-report) * Screens as obese (BMI \> 30 kg/m2) or overweight (BMI of 25 - 29.9 kg/m2) (per height and weight measurement in person or remotely) * Owns a cell phone capable of receiving text messages (per self-report) * Owns an internet connected device (e.g. cell phone, tablet, etc.) capable of conducting videoconference calls (per self-report) * Agrees to be audio-recorded (per self-report) Phase 2 (child participants) * Age 8-12 years (per parent self-report) * Has a parent or primary caregiver who is eligible and participating in Phase 2 (per parent self-report) Exclusion Criteria: Phase 1 * Is pregnant or might be pregnant (per self-report) * Presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (individuals with hypertension and diabetes mellitus may still participate) that may affect diet and study participation (per self-report) * Has dietary restrictions, i.e. liquid diet, that may affect diet and study participation (per self-report) * Has a household member who has already participated or agreed to participate in this study program (per self-report) * Prior participation in one of our preliminary studies, e.g., COMIDA, SANOS, Family COMIDA (per self-report) and any related focus groups * Works for or with the VDS or MHU (per self-report) * Presence of cognitive impairment disorder (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection (per study team) Phase 2 (parent participant) * Is pregnant or might be pregnant (per self-report) * For women, is lactating (per self-report) * Presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (individuals with hypertension and diabetes mellitus may still participate) that may affect diet and study participation (per self-report) * Has dietary restrictions, i.e., liquid diet, that may affect diet and study participation (per self-report) * Has physical activity restrictions, i.e., handicapped or mobility issues, that may affect physical activity participation (increasing step counts; per self-report) * Has a household member who has already participated or agreed to participate in this study program (per self-report) * Prior participation in one of our preliminary studies, e.g., COMIDA, SANOS, Family COMIDA (per self-report) and any related focus groups * Works for or with the VDS or MHU (per self-report) * Presence of cognitive impairment disorder (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection (per study team) * Has been prescribed Ozempic, Wegovy, Mounjaro, Rybelsus, Trulicity (or other GLP 1 receptor agonist), or any other drug to treat obesity (per self-report) or (if previously prescribed) 7 weeks have not passed since the last dose was taken. * Has undergone weight loss/bariatric surgery (RYBG, gastric banding, sleeve gastrectomy, balloon, etc.) or is planning to undergo such surgery in the next 12 months (per self-report) Phase 2 (child participant) * Has dietary restrictions, i.e., liquid diet, that may affect diet and study participation (per parent self-report) * Has physical activity restrictions, i.e., handicapped or mobility issues, that may affect physical activity participation (per parent self-report) * Has an eating disorder (per parent self-report) * Is underweight (per parent self-report)
Where it's running
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, United States Recruiting
Study contacts
- Principal investigator: Jennifer Leng, MD, MPH — Memorial Sloan Kettering Cancer Center
- Study coordinator: Jennifer Leng, MD, MPH
- Email: lengj@mskcc.org
- Phone: 646-888-8057
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Fasted versus fed aerobic exercise for weight loss and heart health
This 16-week program will see if doing aerobic exercise before breakfast (fasted) versus after eating helps adults with overweight or obesity lose more weight and improve heart-related measures.
-
Personalized weight-loss medication plan for adults with bipolar disorder
This pilot tests whether matching FDA-approved weight-loss medicines to specific obesity types helps adults aged 18–65 with bipolar disorder lose weight.
-
Efsubaglutide alfa for weight loss after metabolic surgery
This trial will test whether efsubaglutide alfa helps people who remain obese six months after metabolic surgery lose weight and improve obesity-related health problems.
-
Protein supplements with semaglutide and a calorie-restricted diet for weight loss
This will test whether adding daily protein supplements to semaglutide plus a calorie-restricted diet helps adults with overweight or obesity lose more weight, preserve muscle, and reduce weight regain.
-
Probiotic or semaglutide plus diet to reduce body weight
This project will test whether adding a probiotic (Lactobacillus paracasei LC-19) or semaglutide to a calorie-restricted diet helps overweight adults lose weight and improve blood sugar and lipid levels.
-
Effects of CONTRAVE on weight loss and behavior in adults with obesity
This study is testing if the weight-loss drug CONTRAVE can help adults with obesity lose weight and manage their appetite better when combined with a diet.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.